Selective Detection of Human Lung Adenocarcinoma Cells Based on the Aptamer-Conjugated Self-Assembled Monolayer of Gold Nanoparticles

Nguyen, Ngoc-Viet; Jen, Chun-Ping

doi:10.3390/mi10030195

Cited by 26 publications

(13 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Schematic illustration of the electrochemical‐based biosensor developed CTC detection and isolation (reprinted from, 44 fig. 2, published and licensed by MDPI, according to Creative Common CC BY license; http://creativecommons.org/licenses/by‐nc/3.0/)…”

Section: Cancer Detectionmentioning

confidence: 99%

Biosensors based on aptamer‐conjugated gold nanoparticles: A review

Nooranian

Mohammadinejad

Mohajeri

et al. 2021

Biotech and App Biochem

View full text Add to dashboard Cite

Simply synthetized gold nanoparticles have been highly used in medicine and biotechnology as a result of their biocompatibility, conductivity, and being easily functionalized with biomolecules such as aptamer. Aptamer-conjugated gold nanoparticle structures synergically possess characteristics of both aptamer and gold nanoparticles including high binding affinity, high biocompatibility, enhanced target selectivity, and long circulatory half-life. Aptamer-conjugated gold nanoparticles have extensively gained considerable attention for designing of biosensing systems due to their interesting optical and electrochemical features. Moreover, biosensors based on aptamer-gold nanoparticles are easy to use, with fast response, and inexpensive which make them ideal in individualized medicine, disease markers detection, food safety, and so forth. Moreover, due to high selectivity and biocompatibility of aptamer-gold nanoparticles, these biosensing platforms are ideal tools for targeted drug delivery systems. The application of this nanostructure as diagnostic and therapeutic tool has been developed for detection of cancer in the early stage by detecting cancer biomarkers, pathogens, proteins, toxins, antibiotics, adenosine triphosphate, and other small molecules. This review obviously demonstrates that this nanostructure effectively is applicable in the field of biomedicine and possesses potential of commercialization aims. K E Y W O R D S aptamer, biosensor, gold nanoparticles 1 42 CTCs Human Caucasian Burkitt′s lymphoma Electrochemical 4 cells/ml * 43 Acute lymphoblastic leukemia 3 cells/mL * Non-small cell lung cancer Electrochemical * * 44 Human acute lymphoblastic leukemia Electrochemical * * 48

show abstract

Section: Cancer Detectionmentioning

confidence: 99%

Biosensors based on aptamer‐conjugated gold nanoparticles: A review

Nooranian

Mohammadinejad

Mohajeri

et al. 2021

Biotech and App Biochem

View full text Add to dashboard Cite

show abstract

“…A limit of detection of 1.5 × 10 4 cells/mL was calculated. More recently, they have further upgraded their impedimetric biosensor by introducing gold nanoparticles into their system for enhanced sensitivity [51]. Here, the microfluidic biosensor uses 3-electrode configuration for the selective detection of the same A549 circulating tumor cells.…”

Section: Impedimetric Detectionmentioning

confidence: 99%

Lab-on-a-Chip Systems for Aptamer-Based Biosensing

Khan

Song

2020

Micromachines

View full text Add to dashboard Cite

Aptamers are oligonucleotides or peptides that are selected from a pool of random sequences that exhibit high affinity toward a specific biomolecular species of interest. Therefore, they are ideal for use as recognition elements and ligands for binding to the target. In recent years, aptamers have gained a great deal of attention in the field of biosensing as the next-generation target receptors that could potentially replace the functions of antibodies. Consequently, it is increasingly becoming popular to integrate aptamers into a variety of sensing platforms to enhance specificity and selectivity in analyte detection. Simultaneously, as the fields of lab-on-a-chip (LOC) technology, point-of-care (POC) diagnostics, and personal medicine become topics of great interest, integration of such aptamer-based sensors with LOC devices are showing promising results as evidenced by the recent growth of literature in this area. The focus of this review article is to highlight the recent progress in aptamer-based biosensor development with emphasis on the integration between aptamers and the various forms of LOC devices including microfluidic chips and paper-based microfluidics. As aptamers are extremely versatile in terms of their utilization in different detection principles, a broad range of techniques are covered including electrochemical, optical, colorimetric, and gravimetric sensing as well as surface acoustics waves and transistor-based detection.

show abstract

“…Fusion of a self-assembled monolayer (SAM) of AuNP and determined aptamer on gold microelectrodes for target cells trapping fabricated a biosensor with high quantification stability operable for early lung cancer detection. The S-Au bonds between thiol-terminated aptamers and AuNP layers showed considerable selectivity assay for A549 lung CTCs cells capturing in the whole blood samples [85]. Commercialisation and mass production of user-friendly biosensors for liquid biopsy has been expanded.…”

Section: Electrochemical Sensormentioning

confidence: 99%

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)

et al. 2021

View full text Add to dashboard Cite

Globally, non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths. Despite advancements in chemotherapy and targeted therapies, the 5-year survival rate has remained at 16% for the past forty years. Minimal residual disease (MRD) is described as the existence of either isolated tumour cells or circulating tumour cells in biological liquid of patients after removal of the primary tumour without any clinical signs of cancer. Recently, liquid biopsy has been promising as a non-invasive method of disease monitoring and treatment guidelines as an MRD marker. Liquid biopsy could be used to detect and assess earlier stages of NSCLC, post-treatment MRD, resistance to targeted therapies, immune checkpoint inhibitors (ICIs) and tumour mutational burden. MRD surveillance has been proposed as a potential marker for lung cancer relapse. Principally, biosensors provide the quantitative analysis of various materials by converting biological functions into quantifiable signals. Biosensors are usually operated to detect antibodies, enzymes, DNA, RNA, extracellular vesicles (EVs) and whole cells. Here, we present a category of biosensors based on the signal transduction method for identifying biosensor-based biomarkers in liquid biopsy specimens to monitor lung cancer treatment.

show abstract

Selective Detection of Human Lung Adenocarcinoma Cells Based on the Aptamer-Conjugated Self-Assembled Monolayer of Gold Nanoparticles

Cited by 26 publications

References 45 publications

Biosensors based on aptamer‐conjugated gold nanoparticles: A review

Biosensors based on aptamer‐conjugated gold nanoparticles: A review

Lab-on-a-Chip Systems for Aptamer-Based Biosensing

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)

Contact Info

Product

Resources

About